Modified Hydrogels for Reduced Enzyme Exposure in Prodrugs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hydrogel-linked prodrugs face challenges due to drug molecules attached to the outside of the hydrogel being exposed to enzymes and potentially causing immune reactions or inflammations, as well as having residual activity.
Innovation Solution
A process to modify hydrogels by reducing the number of functional groups on their surface through the use of a spacer reagent and an inert PEG-based polymer, limiting the amount of drug loading on the outside, thereby minimizing exposure to enzymes and reducing immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If drug molecules are attached to the outside of the hydrogel carrier, then drug loading capacity is improved, but exposure to enzymes and immunogenicity increases
Solution Approach 1:
The patent introduces PEG-based polymers as intermediary substances that modify the hydrogel surface. These PEG chains act as a physical barrier between the drug molecules and the biological environment, preventing enzyme access while maintaining drug loading capacity. The PEG polymer serves as a mediator that decouples the drug from direct exposure to harmful biological factors.
Solution Approach 2:
The patent applies different functional characteristics to different regions of the hydrogel carrier. The interior regions maintain high drug loading capacity with functional groups for drug attachment, while the exterior surface is modified with PEG chains to create an enzyme-resistant, immunogenicity-reduced interface. This spatial differentiation of properties resolves the contradiction between drug loading and safety.
2Adaptability or versatility
If functional groups are present on the hydrogel surface, then drug attachment capability is improved, but immunogenicity and enzyme exposure increase
Solution Approach 1:
The patent segments the hydrogel structure into distinct functional zones: internal regions containing drug-attachment functional groups, and an external PEG-modified layer that provides biocompatibility. This segmentation allows the functional groups to perform their attachment function without directly exposing their potentially harmful effects to the biological environment.
Solution Approach 2:
The patent creates a composite structure combining the hydrogel matrix with PEG-based polymer modifications on the surface. This composite material integrates the drug-attachment capabilities of the hydrogel with the immunogenicity-reducing properties of PEG, achieving both high adaptability and low harmful effects simultaneously.
Data Source
AI summary
The present invention relates to a process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug, to hydrogels obtainable from said process, the use of such hydrogel as a carrier in a hydrogel-linked prodrug and to hydrogel-linked prodrugs comprising a covalently conjugated hydrogel of the present invention. The hydrogel prodrug carrier has a reduced drug loading on the outside of the hydrogel carrier. This is achieved by reducing the number of functional groups of the hydrogel, in particular those at its surface.